Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Last updated: March 31, 2026
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

1

Condition

Astrocytoma

Gliomas

Treatment

Allogeneic Adipose-derived Mesenchymal Stem Cells

Magnetic Resonance Imaging

Biospecimen Collection

Clinical Study ID

NCT05789394
MC220704
21-004561
NCI-2023-02057
  • Ages > 18
  • All Genders

Study Summary

This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fields. Despite this aggressive therapy, the survival after finishing treatment remains low and the disease often reoccurs. Unfortunately, the available therapy options for recurrent glioblastoma are minimal and do not have a great effect on survival. AMSCs are found in body fat and when separated from the fat, are delivered into the surgical cavity at the time of surgery. When in direct contact with tumor cells, AMSCs affect tumor growth, residual tumor cell death, and chemotherapy resistance. The use of AMSCs delivered locally into the surgical cavity of recurrent glioblastoma during a craniotomy could improve the long-term outcomes of these patients by decreasing the progression rate and invasiveness of malignant cells.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants >= 18 years

  • Karnofsky Performance Scale (KPS) >= 60

  • Negative pregnancy test done =< 7 days prior to registration, for persons ofchildbearing potential only

  • Patients with a previous histological diagnosis of glioblastoma multiforme,isocitrate dehydrogenase (IDH) wildtype (WT) or astrocytoma, IDH-mutant World HealthOrganization (WHO) grade IV according to the 2021 WHO classification of tumors ofthe central nervous system , who are candidates to- and will undergo a redocraniotomy for excision of recurrent tumor

  • There is measurable disease according to the immunotherapy response assessment inneuro-oncology (iRANO) criteria

  • Serum creatinine and urea <= 2 times the upper limit of normal (=< 3 weeks prior toregistration)

  • Alanine transaminase (ALT), aspartate transferase (AST) and alkaline phosphatase =< 3 times the upper limit of normal, and bilirubin =< 2.5 mg/dL (=< 3 weeks prior toregistration)

  • Prothrombin time =< 1.5 times upper limit of normal (=< 3 weeks prior toregistration)

  • International normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5times the upper limit of normal (=< 3 weeks prior to registration)

  • Hemoglobin >= 9 g/dL (=< 3 weeks prior to registration)

  • Platelets >= 100 x 10^9/L (=< 3 weeks prior to registration)

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (=< 3 weeks prior to registration)

  • Willing to return to enrolling institution for follow-up (during the activemonitoring phase of the study)

  • Patient or legally authorized representative (LAR) is able to fully understand andprovide written and verbal consent for the protocol

  • Willingness to provide mandatory blood specimens for correlative research

  • Willingness to provide mandatory tissue specimens for correlative research

  • Willingness to undergo Ommaya reservoir placement and provide cerebrospinal fluid (CSF) samples for correlative research

Exclusion

Exclusion Criteria:

  • Patients who are undergoing needle biopsy only or non-eligible for a surgicalintervention

  • Tumors located solely in the brain stem, midbrain, or thalamus withoutinclusion/involvement of surrounding brain matter

  • Previous treatment with bevacizumab

  • Radiographic evidence of leptomeningeal disease

Study Design

Total Participants: 20
Treatment Group(s): 5
Primary Treatment: Allogeneic Adipose-derived Mesenchymal Stem Cells
Phase: 1
Study Start date:
June 16, 2023
Estimated Completion Date:
July 24, 2027

Study Description

PRIMARY OBJECTIVE:

I. To establish the maximum tolerated dose (MTD) of locally delivered adipose-derived mesenchymal stem cells (AMSCs) in patients with recurrent glioblastoma (GBM).

SECONDARY OBJECTIVES:

I. To assess the safety and toxicity profile of locally delivered AMSCs in patients with recurrent GBM.

II. To assess overall survival (OS) in recurrent GBM patients treated with locally delivered AMSCs.

III. To assess progression free survival (PFS) in recurrent GBM patients treated with locally delivered AMSCs.

CORRELATIVE OBJECTIVES:

I. To explore the systemic immune response after application of AMSCs through cytokine analysis on peripheral blood samples.

II. To explore the local changes on the brain parenchyma by analyzing tissue at recurrence.

III. To explore the presence of AMSCs on brain tissue at recurrence.

OUTLINE: This is a dose-escalation study.

Patients receive AMSCs intratumorally (IT) and undergo Ommaya reservoir placement during a craniotomy on study. Patients also undergo magnetic resonance imaging (MRI) on study and during follow-up, as well as blood sample, tissue sample and cerebrospinal fluid (CSF) sample collection on study.

After completion of study treatment patients are followed up every 2 months for 1 year.

Connect with a study center

  • Mayo Clinic in Florida

    Jacksonville, Florida 32224-9980
    United States

    Active - Recruiting

  • Mayo Clinic in Florida

    Jacksonville 4160021, Florida 4155751 32224-9980
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.